Trial Profile

ED50 and ED95 of Remimazolam Intravenous Bolus on the Loss of Consciousness in Patients Undergoing General Anesthesia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remimazolam (Primary)
Indications Anaesthesia
Focus Therapeutic Use

Most Recent Events

10 May 2022 Results evaluating the efficacy and safety of i.v. bolus remimazolam during induction of anaesthesia, published in the British Journal of Anaesthesia
26 Jul 2021 Status changed from recruiting to completed.
21 Jul 2021 Planned End Date changed from 20 May 2022 to 20 Aug 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com